• Home / GORE® PROPATEN® Vascular Graft /
Challenge: Improving Thromboresistance and Patency of Vascular Grafts*

Choice: GORE® PROPATEN® Vascular Graft

Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons.

The GORE® PROPATEN® Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.

Anything better below-knee would be a vein

Overall weighted average* primary patency based on GORE® PROPATEN® Vascular Graft literature in below knee bypasses

*See references (PDF)

The GORE® PROPATEN® Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism serves to anchor heparin molecules to the luminal surface while still maintaining heparin’s intrinsic bioactive properties. The result: a thromboresistant BioActive graft surface that retains its bioactive properties.

The GORE® PROPATEN® Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. The thromboresistant surface technology employed on the GORE® PROPATEN® Vascular Graft is designed to maintain bioactivity, thus increasing the potential for performance improvement and increased patency*.

*Long-term data are not available regarding improved patency compared to marketed grafts.




The BioActive luminal surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft (top) remains free of thrombus, while the non-bioactive surface of a control graft (below; 3 mm diameter) is covered with thrombus. Grafts were explanted after 2 hours in a challenging carotid shunt canine model.